Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Preclinical and first-in-human of Purinostat Mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed or refractory multiple myeloma and lymphoma [PDX]

ABSTRACT: Preclinical and first-in-human of Purinostat Mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed or refractory multiple myeloma and lymphoma [PDX]

PROVIDER: PRJNA1261791 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Preclinical and first-in-human of Purinostat Mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed or refractory multiple myeloma and lymphoma [PDX]

Project description:Purinostat Mesylate (PM), a highly selective HDAC I/IIb inhibitor, exhibits excellent antitumor activity in multiple MM and lymphoma cell lines and multiple mouse models, outperforming the pan-HDAC inhibitor panobinostat or first-line/second-line multi-drug combinations. Different from panobinostat, bulk RNA-seq analysis results revealed that PM targeted essential tumor survival factors, and triggered inflammation and interferon responses. ScRNA-seq of 5TMM models further indicated that PM enhanced antitumor immunity by boosting monocyte- and T cell-mediated immune responses.

2025-05-15 | GSE296833 | GEO

Preclinical and first-in-human of Purinostat Mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed or refractory multiple myeloma and lymphoma

2025-05-15 | GSE296835 | GEO

Preclinical and first-in-human of Purinostat Mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed or refractory multiple myeloma and lymphoma

Project description:Preclinical and first-in-human of Purinostat Mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed or refractory multiple myeloma and lymphoma

| PRJNA1261787 | ENA

Genomic Analysis of Relapsed/Refractory DLBCL

Project description:Genomic Analysis of Relapsed/Refractory DLBCL

| PRJNA1200818 | ENA

DNA methylation of Relapsed/Refractory AML

Project description:DNA methylation of Relapsed/Refractory AML

| PRJNA934390 | ENA

Genomic Analysis of Relapsed/Refractory DLBCL

Project description:Genomic Analysis of Relapsed/Refractory DLBCL

| PRJNA1200817 | ENA

DNA methylation of Relapsed/Refractory AML

Project description:Genome wide DNA methylation profiling of blood and bone marrow of Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia. The Illumina Infinium EPIC Human DNA methylation Beadchip was used to obtain DNA methylation profiles across over 860,000 CpGs.

2023-12-31 | GSE225239 | GEO

ViPOR in Relapsed/Refractory B-Cell Lymphoma

Project description:ViPOR in Relapsed/Refractory B-Cell Lymphoma

| PRJNA1090979 | ENA

Genomic profiling of relapsed and refractory childhood cancers

Project description:Genomic profiling of relapsed and refractory childhood cancers

| PRJNA661354 | ENA

Genomic profiling of relapsed and refractory childhood cancers

Project description:Genomic profiling of relapsed and refractory childhood cancers

| PRJNA661355 | ENA